Intellectual Property
Icahn Steals The Future of Enzon Pharmaceuticals
Enzon Pharmaceuticals, on the reported urging of uber-investor Carl Icahn, will spin off a NewCo along with the majority of the company’s core technology (PEGylation), their entire published preclinical pipeline (i.e.; their RNA antagonist oncology portfolio) and $150m of funding from Enzon. Not a bad way to start a company, right?
Maybe I’m way off [...]
Does the Esperion Spin-Off Signal the Start of New R&D Era?
What a difference time makes. Pfizer acquired Esperion roughly 4 years ago at a 53% premium and a price tag of $1.3 billion dollars. Yesterday, Esperion was spun off from Pfizer and raised ~$23m from VCs to continue operation, with no other financial terms disclosed. Esperion had been operating as a separate research division inside [...]
Biotech/Pharma Competitive Intelligence
Introduction
A significant chunk of my job in business development entails competitive intelligence and I’ve found the lack of biotech/pharmaceutical specific guide in this area a bit distressing. In that vein, I’ve tried to compile a guide / list of services and hacks I currently use to keep up on the industry in general and [...]
Top Biopharma Deals Q1 ‘08
It’s a just a quarter of the way into 2008 and it is clear the both large
biotech and pharma have holes to fill in thier pipeline. Six deals have
already been inked that total over a half a billion bio-dollars each.
Below are 4 of the top deals thus far:
Genzyme/Isis ($1,900M) - Genzyme paid Isis $175M in
cash [...]
Recent Comments